Pharmaceuticals

Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

* Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investme...

2026-04-10 08:30 6739

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application (NDA) for its...

2026-04-10 08:00 9652

FDA Accepts NDA for TLX101-Px (Pixclara®)

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company's resubmitted New Drug Application (NDA) for TLX101-Px[1],...

2026-04-10 06:50 6793

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the ...

2026-04-09 21:00 7601

Terra Quantum AG to go public in $3.25 billion SPAC deal

Strategic go-public transaction aims to accelerate growth in quantum technologies and expand global market reach ST. GALLEN, Switzerland and INCLINE VILLAGE, Nev. , April 9, 2026 /PRNewswire/ -- Terra Quantum AG ("Terra Quantum"), a leading quantum technology company, and Mountain Lake Acquisiti...

2026-04-09 19:16 3953

OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

ROCKVILLE, Md., April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug (IND) application for a Phase 1/2 clinical trial of ONC-841, the company's investigational...

2026-04-09 19:00 5663

Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development

CHENGDU, China, April 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to Rule 18A.12 of the Rules Governin...

2026-04-09 18:33 5915

World's First CAR-T Therapy for Solid Tumors Available in China Soon

A New Hope for Patients with Advanced Gastric and Pancreatic Cancers SHANGHAI, April 9, 2026 /PRNewswire/ -- A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer tr...

2026-04-09 13:36 4993

World's First CAR-T Therapy for Solid Tumors Available in China Soon

A New Hope for Patients with Advanced Gastric and Pancreatic Cancers SHANGHAI, April 9, 2026 /PRNewswire/ -- A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer tr...

2026-04-09 13:28 5201

Telix Strengthens Board with Additional Director Appointments

MELBOURNE, Australia and INDIANAPOLIS, April 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026[1] , as part of Board expansion and succession planning: ...

2026-04-09 06:58 5148

"Lactobacillus Rhamnosus L34": A Native Probiotic That Reduces Inflammation in Patients with Chronic Kidney Disease

BANGKOK, April 8, 2026 /PRNewswire/ -- Researchers from the Faculty of Medicine at Chulalongkorn University have identified a native probiotic strain, Lactobacillus rhamnosus L34, that may help reduce inflammation and toxin buildup in pa...

2026-04-08 16:56 5007

Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited

* Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products * Aggregate consideration of USD250,000,000 (approximately RMB1,721,650,000), payable in three installments * Delivers near-term revenue and profitability wi...

2026-04-08 10:21 11777

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-lif...

2026-04-07 19:00 8507

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 Highlights * Q1 2026 unaudited ...

2026-04-07 06:57 7142

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continu...

2026-04-03 04:34 6259

Lupin Completes Acquisition of VISUfarma

MUMBAI, India and LONDON and ROME and ZUG, Switzerland, April 2, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty...

2026-04-02 15:00 4958

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May...

2026-04-02 06:59 5732

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint

SUZHOU, China, April 1, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceu...

2026-04-01 22:44 6401

NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies...

2026-04-01 07:00 4966

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil™ system in Toronto

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing of clinical supplies and commercial products. TORONTO, March 31, 2026 /PRNewswire/ -- Dalton Pharma Services today announced the successful installation of its RoboFil™ aseptic p...

2026-03-31 22:00 3647
1 ... 13141516171819 ... 184